Polatuzumab Vedotin

Phase 3

Roche Holding AG (RHHBY)

00%

What is LOA?

Phase 3

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

Upcoming Catalysts

What are catalysts?

Q3 '27

RHHBYPhase 2$316.4B

Polatuzumab vedotin Phase 2 Est. Readout

Polatuzumab Vedotin• Non-Hodgkin's Lymphoma99

Q3 2027~QConfirmed

CT.gov

00%

Competitive Landscape

0 competitors in Non-Hodgkin's Lymphoma

View Full Landscape

Drug Information

Target Indication

Non-Hodgkin's Lymphoma

Clinical Trial

NCT02611323

Last updated: 2/10/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Regulatory Approvals

EMA1/16/2020

Polivy

Polivy in combination with bendamustine and rituximab is indicated for the treatment of adult patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) who are not candidates for haematopoietic stem cell transplant. Polivy in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone (R-CHP) is indicated for the treatment of adult patients with previously untreated diffuse large B-cell lymphoma (DLBCL).

OrphanPRIME

View on EMA

Drug Science

Mechanism of action & safety profile

Developer

RHHBY

Roche Holding AG

Biotechnology•Europe•NYSE

Related Pipeline

RO7204239Phase 3

Obesity

trastuzumab (Herceptin®)Phase 3